Having the ARVO meeting in any of various locations enables the group to accommodate more program
options and have a variety of hotel options nearby.
Month: May 2012
Ophthalmologists slightly better off than primary care colleagues
Ophthalmologists expressed a little more optimism than primary-care physicians, when asked to evaluate
the financial state of their practices in a national survey conducted in 2011.
Dry eye brimming with innovation
The acceleration of research focused on dry eye over the past several decades has led to an increase
in knowledge regarding the pathophysiology of the disease.
Tear layer approach effective for dry eye
The tear layer approach is effective in the diagnosis and treatment of dry eye syndrome.
Lessons for a lifetime
The golden rule, a maxim the author learned in kindergarten, remains crucial to his practice of
medicine today.
Challenges, opportunities arise
The world of glaucoma management in 2012 is feeling the impact of not only a variety of challenges,
but also new opportunities.
Tailor treatment for dry eye
Dry eye comes in a variety of guises and, once diagnosed, may require various therapeutic
options.
NSAIDs safe in select patients
Topical branded nonsteroidal anti-inflammatory drugs are safe to use in patients with evaporative dry
eye syndrome and in those with meibomian gland dysfunction.
Studies support targeting IOP
Results from randomized controlled clinical trials investigating populations covering the spectrum
from ocular hypertension to advanced glaucoma provide clear evidence that for most patients, glaucoma is an
IOP-sensitive optic neuropathy for wh…
Recognizing childhood glaucoma in the primary pediatric setting
Pediatric glaucoma, if not diagnosed early and treated promptly, can lead to significant corneal and
optic nerve damage and loss of vision in infants and young children.
Longer follow-up needed with bevacizumab for ROP
NEW YORK (Reuters Health) – Babies treated with bevacizumab injection for retinopathy of prematurity
(ROP) need close follow-up for longer than previously thought, new data show.
FDA Actions in Brief April 2012
Recent FDA Approvals (through April 2012) related to (Johnson & Johnson, AstraZeneca,
Affymax, Takeda Pharmaceutical, Teva Pharmaceutical Industries, Avioq, Hope Pharmaceuticals, Novo Nordisk, Avid
Radiopharmaceuticals)